Latest Soft tissue sarcoma Stories
Eisai Demonstrates Commitment to Patients with Rare Cancers WOODCLIFF LAKE, N.J., Feb. 25, 2015 /PRNewswire/ -- Eisai Inc.
MADRID, February 3, 2015 /PRNewswire/ -- PharmaMar announces that the U.S.
RARITAN, N.J., Feb. 3, 2015 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S.
Aldoxorubicin Demonstrates 2-Fold Increase in Likelihood of Surviving More than 2 Years versus Doxorubicin and 27% Reduction in the Risk of Death LOS ANGELES, Jan.
Aldoxorubicin Showed 66% Complete or Partial Responses and No Tumor Progression in KS Patients with Excellent Tolerability LOS ANGELES, Jan.
Additionally, Trabectedin Expanded Access Program Now Allows Entry of Eligible Patients with Previously Treated Advanced Soft Tissue Sarcoma, Including those with Liposarcoma and Leiomyosarcoma
ROCKVILLE, Md., Nov.
LOS ANGELES, Oct.
Trial Has Not Yet Reached Necessary Number of Survival Events to Report on Overall Survival Due to Longer than Expected Survival of Study Patients LOS ANGELES, Oct.
- A person in a secondary role, specifically the second most important character (after the protagonist).